Gene Therapy for Aging and Longevity (Paper June 2026)

Key Takeaways

• AAV telomerase therapy extended mouse lifespan without increasing cancer.
• Human longevity genes only partially overlap with mouse lifespan genes.
• Whole‑body delivery remains the biggest hurdle for aging gene therapies.
• Partial reprogramming shows promise but carries cancer and identity risks.
• Long‑lived species provide novel gene candidates for future interventions.

Pulse Analysis

The review positions aging as a genetically tractable process, summarizing dozens of mouse studies where single‑gene interventions—most notably AAV‑mediated TERT, SIRT6, KL and ATG5—produced measurable lifespan extensions and improved tissue function. These findings reinforce the hypothesis that key longevity pathways can be amplified or restored, offering a mechanistic foothold for therapeutic development. However, the translational gap remains wide, as human genetic association data only modestly corroborate many of the mouse‑identified targets, underscoring the need for cross‑species validation before clinical pursuit.

Delivery technology emerges as the decisive bottleneck. While adeno‑associated viruses dominate current clinical pipelines due to their safety profile, their limited cargo capacity, pre‑existing immunity, high manufacturing costs, and difficulty achieving uniform systemic distribution constrain their utility for whole‑body rejuvenation. Alternative platforms such as lentiviral vectors, adenoviral vectors and lipid nanoparticles provide niche advantages—ex‑vivo cell engineering or transient protein expression—but none yet reconcile the scale, durability, and safety required for preventive therapy in otherwise healthy older adults. Consequently, the field is pivoting toward hybrid approaches that combine gene addition with precise editing and controllable expression systems.

Looking ahead, the authors argue that evolutionary insights from exceptionally long‑lived species and the emerging field of partial cellular reprogramming could unlock more potent interventions. Molecules derived from naked mole‑rat hyaluronic acid synthase or bowhead whale DNA‑repair proteins illustrate how nature’s own longevity solutions may be repurposed. Yet, the promise of OSK/OSKM‑based reprogramming is tempered by oncogenic and identity‑loss risks, demanding rigorous safety frameworks. Ethical considerations—access, enhancement versus therapy, and appropriate clinical endpoints—must evolve in parallel with the science to guide regulatory pathways and ensure that longevity gene‑therapy, when realized, delivers equitable health benefits.